Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. - Test2 - elhamkhani - TriplyDB

Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations.

Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations.

http://www.wikidata.org/entity/Q38336102

about

Research priorities in sarcomeric cardiomyopathies Unclassifiable arrhythmic cardiomyopathy associated with Emery-Dreifuss caused by a mutation in FHL1.Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects Genetics of hypertrophic cardiomyopathy: A review of current state.Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.Myofilament protein dynamics modulate EAD formation in human hypertrophic cardiomyopathy.Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.Life-long tailoring of management for patients with hypertrophic cardiomyopathy : Awareness and decision-making in changing scenarios.Supplementary Diagnostic Landmarks of Left Ventricular Non-Compaction on Magnetic Resonance Imaging.Sarcomeric cardiomyopathies: from bedside to bench and back.Editorial highlights from Cardiovascular Research.Myosin Rod Hypophosphorylation and CB Kinetics in Papillary Muscles from a TnC-A8V KI Mouse Model.Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.Follow-up and prognosis of HCM

P2860

Q27694507-F090169B-34E6-4B19-818E-E3FBCBA7FF62 Q33429853-0E0AAAB8-E67F-48F4-A7EC-1E35907D3E41 Q36448934-4D4F2199-0CEC-488A-B932-198F0D228560 Q38736063-55B6A52D-125E-4941-996A-2F74BE53F184 Q38874111-F387B2A5-D202-465A-BF54-94F093145724 Q39397322-59B8C65C-1630-4FD4-B0E1-90DDE9A30815 Q41627235-8FF8D6EA-D625-495C-A2A2-EC528C1EF785 Q42320941-8C6603FF-762C-4616-9735-65A792CAC459 Q47129985-0B902130-BBE3-4B78-B83D-DAD150248898 Q48750044-2630BD88-9878-4C23-9F4C-054303EBEBBE Q49549470-21A8183A-D8A9-485D-A057-29FB5126201C Q51033685-B2FA9801-A0DA-4557-AD4F-AAA2C3F2D842 Q55410018-80BFECBA-B7C4-4109-A3B9-B46E3EEDEF57 Q58565523-78C16D6C-0693-411F-BE53-B030BA029DAE

P2860

Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations.

http://www.wikidata.org/entity/Q38336102

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Defining phenotypes and diseas ...... le of clinical investigations.

@en

type

label

Defining phenotypes and diseas ...... le of clinical investigations.

@en

prefLabel

Defining phenotypes and diseas ...... le of clinical investigations.

@en

P1433

Q38336102-CF9E55E9-240D-4661-A435-77736493C65A

P1476

Q38336102-8128B50F-F8E6-4E87-A75E-42F220058D07

P2093

Q38336102-26567DBD-FFE3-420A-BCE1-B10B52E4D5FB

Q38336102-2E68D651-BEB7-40CF-96FA-550E7C4528E2

Q38336102-38BCD913-057F-485F-8ABA-28C3D45FBD6E

Q38336102-5837AF64-E447-41E9-A583-5F2E507947B5

Q38336102-7D218858-CD03-4F2D-8CCB-012EBAA2110B

Q38336102-7ECE7275-6DCE-4489-B742-9EC8D6EB0FC5

Q38336102-81C1FD94-14D4-4E78-A8ED-7C8A6F66E266

Q38336102-ABC882FF-66A2-4F00-8F37-B5C64F3DF479

Q38336102-CDF1892C-D460-4687-A574-4072FD76CAC4

Q38336102-FEB18A1A-97EC-472A-8E9E-8D1ECE6D0786

P2860

Q38336102-0513D393-FAA0-4124-A1A7-F95DCE564207

Q38336102-0E4BE635-0414-4ED0-B5A0-B8D58B03D634

Q38336102-112D8ABA-1E34-469C-96A0-E1642254CA78

Q38336102-17678BDD-B24E-49AF-8938-984546A968FC

Q38336102-17E13C98-9690-4887-AF4E-34BE435CEE22

Q38336102-1E910256-D2AF-43E4-BC2C-66F12B55311B

Q38336102-1F5D30C1-8270-41D3-802B-3FD23AC9CC35

Q38336102-22A9247A-072A-4023-9311-80854143C447

Q38336102-26E7EF1E-3EF6-4C26-AE1D-433B644B3004

Q38336102-285A3F39-24A8-4038-8791-B784820EA4CD

P304

Q38336102-FF8F36AE-BDAD-4EB3-9184-F8FACFF44D14

P31

Q38336102-8473CDDA-0F14-43BD-9D21-57364D046463

P356

Q38336102-20E3C190-2A63-40E4-A311-6799376D4DB5

P433

Q38336102-10FEDC99-49D2-4910-8484-AFEE12384BE8

P478

Q38336102-7A71DA42-4EC8-4B63-A09E-EBF39CECD2C8

P577

Q38336102-86174736-FE50-41BE-AD3C-B0D71E80B663

P698

Q38336102-D27A672E-150F-4F88-A8BD-E29AFD73959D

P356

P1433

Cardiovascular Research

P1476

Defining phenotypes and diseas ...... le of clinical investigations.

@en

P2093

Albert Van Rossum

http://www.w3.org/2001/XMLSchema#string

Benedetta Tomberli

http://www.w3.org/2001/XMLSchema#string

Cristina Basso

http://www.w3.org/2001/XMLSchema#string

Giulia d'Amati

http://www.w3.org/2001/XMLSchema#string

Iacopo Olivotto

http://www.w3.org/2001/XMLSchema#string

Michele Emdin

http://www.w3.org/2001/XMLSchema#string

Michelle Michels

http://www.w3.org/2001/XMLSchema#string

Monica Patten

http://www.w3.org/2001/XMLSchema#string

Paolo G Camici

http://www.w3.org/2001/XMLSchema#string

Yigal Pinto

http://www.w3.org/2001/XMLSchema#string

P2860

Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy

Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making

Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy

Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy

Mutations in sarcomere protein genes in left ventricular noncompaction

Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy

Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia.

Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy.

Conduction abnormalities in pediatric patients with restrictive cardiomyopathy.

P304

409-423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CVR/CVV024

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25631583

http://www.w3.org/2001/XMLSchema#string